| Market cap | $1.11B |
|---|---|
| Enterprise value | $686.49M |
| Revenue | $40.560M |
|---|---|
| EBITDA | -$222.45 |
| Income | -$218.96 |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E | N/A |
|---|---|
| Forward P/E | N/A |
| EV/Sales | 16.93 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 27.27 |
| P/FCF | N/A |
| Price/Book | 2.53 |
| Book/Share | 1.64 |
| Cash/Share | 1.82 |
| FCF yield | -19.09% |
| Volume | 21.537M / 651.228k |
|---|---|
| Relative vol. | 33.07 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | 966.67% |
| Est. EPS Q/Q | -4.50% |
| Profit margin | 0.00% |
|---|---|
| Oper. margin | -639.35% |
| Gross margin | N/A |
| EBIT margin | -541.24% |
| EBITDA margin | -548.45% |
| Ret. on assets | -37.81% |
|---|---|
| Ret. on equity | -46.07% |
| ROIC | -53.69% |
| ROCE | -43.67% |
| Debt/Equity | 0.26 |
|---|---|
| Net debt/EBITDA | 8.45 |
| Current ratio | 9.19 |
| Quick ratio | 9.19 |
| Volatility | 25.77% |
|---|---|
| Beta | 1.80 |
| RSI | 11.39 |
|---|
| Insider ownership | N/A |
|---|---|
| Inst. ownership | N/A |
| Shares outst. | 57.070M |
|---|---|
| Shares float | 39.770M 69.69% |
| Short % of float | 14.42% |
| Short ratio | 10.18 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Wednesday, 27 December 2023
|
|
| Zentalis Pharmaceuticals Is In A Good Position To Deliver On Growth Plans | |
Monday, 6 November 2023
|
|
| Zentalis Pharmaceuticals Inc Reports Q3 2023 Financial Results and Operational Updates | |
Saturday, 12 December 2020
|
|
| Is ZNTL A Good Stock To Buy Now? | |
Wednesday, 3 June 2020
|
|
| Is It Too Late to Jump In on Zentalis? | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Cam Gallagher President and Interim CFO | Sale 31 May 2024 | $114,972 |
| Diana Hausman Chief Medical Officer | Sale 9 May 2024 | $42,353 |
| Melissa B, Epperly Chief Financial Officer | Sale 12 Feb 2024 | $29,435 |
| Cam Gallagher President and Interim CFO | Sale 12 Feb 2024 | $13,419 |
| Mark Lackner Chief Scientific Officer | Sale 1 Feb 2024 | $18,291 |
| Andrea Paul Chief Legal Officer | Sale 1 Feb 2024 | $38,197 |
| Cam Gallagher President and Interim CFO | Sale 1 Feb 2024 | $133,310 |
| Melissa B, Epperly Chief Financial Officer | Sale 1 Feb 2024 | $100,040 |
| Kimberly Blackwell Chief Executive Officer | Buy 13 Nov 2023 | $51,450 |
| David Michael Johnson Director | Buy 10 Nov 2023 | $167,960 |
| Carrie Brownstein Chief Medical Officer | Sale 4 Oct 2023 | $207,246 |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Dr. Anthony Y. Sun M.D. (49) Pres, CEO, and Exec. Chairman | 49 | $957,285 | |
| Dr. Kevin D. Bunker Ph.D. (48) Chief Operating Officer | 48 | $699,495 | |
| Alexis M. Pinto J.D. (54) Chief Legal Officer and Sec. | 54 | $491,126 | |
| Dr. Meena Rao Ph.D. | |||
| Dr. Peter Huang Ph.D. | |||
| Dr. Dimitris Voliotis M.D. (57) Sr. VP of Clinical Devel. | 57 | ||
| Melissa B. Epperly M.B.A. (43) CFO and Treasurer | 43 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
- Health Care > Biotechnology
- Zentalis Pharmaceuticals, Llc, 1359 Broadway, New York 10018, United States
- 212 433 3791
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $40.297 | $30.719 | |||
| Short term investments | $451.368 | $454.881 | |||
| Net receivables | |||||
| Inventory | |||||
| Total current assets | $503.806 | $496.718 | |||
| Long term investments | |||||
| Property, plant & equipment | $40.405 | $41.735 | |||
| Goodwill & intangible assets | $3.736 | $3.736 | |||
| Total noncurrent assets | $53.673 | $54.97 | |||
| Total investments | $451.368 | $454.881 | |||
| Total assets | $557.479 | $551.688 | |||
| Current liabilities | |||||
| Accounts payable | $10.502 | $14.926 | |||
| Deferred revenue | |||||
| Short long term debt | |||||
| Total current liabilities | $54.798 | $69.367 | |||
| Long term debt | $42.616 | $43.15 | |||
| Total noncurrent liabilities | $43.91 | $44.93 | |||
| Total debt | $42.616 | $43.15 | |||
| Total liabilities | $98.708 | $114.297 | |||
| Stockholders' equity | |||||
| Retained earnings | -$878.488 | -$888.556 | |||
| Other stockholder equity | $0.773 | $2.194 | |||
| Total stockholder equity | $458.771 | $437.284 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $30.719 | $45.696 | ||
| Short term investments | $454.881 | $394.302 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $496.718 | $451.933 | ||
| Long term investments | $21.213 | |||
| Property, plant & equipment | $41.735 | $50.078 | ||
| Goodwill & intangible assets | $3.736 | $3.736 | ||
| Total noncurrent assets | $54.97 | $87.377 | ||
| Total investments | $454.881 | $415.515 | ||
| Total assets | $551.688 | $539.31 | ||
| Current liabilities | ||||
| Accounts payable | $14.926 | $11.247 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $69.367 | $56.647 | ||
| Long term debt | $43.15 | $45.166 | ||
| Total noncurrent liabilities | $44.93 | $48.639 | ||
| Total debt | $43.15 | $45.166 | ||
| Total liabilities | $114.297 | $105.286 | ||
| Stockholders' equity | ||||
| Retained earnings | -$888.556 | -$596.365 | ||
| Other stockholder equity | $2.194 | -$1.353 | ||
| Total stockholder equity | $437.284 | $433.803 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $40.56 | ||||
| Cost of revenue | |||||
| Gross profit | $40.56 | ||||
| Operating activities | |||||
| Research & development | $49.585 | $51.557 | |||
| Selling, general & administrative | $15.74 | $16.365 | |||
| Total operating expenses | $65.325 | $67.922 | |||
| Operating income | -$24.765 | -$67.922 | |||
| Income from continuing operations | |||||
| EBIT | $10.155 | -$61.052 | |||
| Income tax expense | $0.143 | -$0.135 | |||
| Interest expense | |||||
| Net income | |||||
| Net income | $10.012 | -$60.917 | |||
| Income (for common shares) | $10.012 | -$60.917 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross profit | ||||
| Operating activities | ||||
| Research & development | $235.158 | $172.734 | ||
| Selling, general & administrative | $64.351 | $54.553 | ||
| Total operating expenses | $299.509 | $227.287 | ||
| Operating income | -$299.509 | -$227.287 | ||
| Income from continuing operations | ||||
| EBIT | -$292.792 | -$237.275 | ||
| Income tax expense | -$0.601 | -$0.469 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$292.191 | -$236.806 | ||
| Income (for common shares) | -$292.191 | -$236.806 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | $10.012 | -$60.917 | |||
| Operating activities | |||||
| Depreciation | $0.324 | $0.337 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $12.833 | $13.88 | |||
| Total cash flows from operations | -$51.974 | -$40.599 | |||
| Investing activities | |||||
| Capital expenditures | -$0.04 | -$0.173 | |||
| Investments | $61.585 | -$41.887 | |||
| Total cash flows from investing | $61.545 | -$42.06 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $0.007 | ||||
| Net borrowings | |||||
| Total cash flows from financing | $0.007 | ||||
| Effect of exchange rate | |||||
| Change in cash and equivalents | $9.578 | -$82.659 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$292.191 | -$236.806 | ||
| Operating activities | ||||
| Depreciation | $1.389 | $1.426 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $54.822 | $46.84 | ||
| Total cash flows from operations | -$207.822 | -$163.751 | ||
| Investing activities | ||||
| Capital expenditures | -$0.583 | -$2.548 | ||
| Investments | -$43.875 | -$111.632 | ||
| Total cash flows from investing | -$44.458 | -$114.18 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $237.303 | $261.043 | ||
| Net borrowings | ||||
| Total cash flows from financing | $237.303 | $261.043 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$14.977 | -$16.888 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | T. Rowe Price Investment Management |
+41.73%
|
3,319,086 | $52,309 |
| 2024 Q1 | Verition Fund Management |
+235.22%
|
1,155,236 | $18,206,519 |
| 2024 Q1 | State Street Corp |
-14.29%
|
3,785,652 | $59,661,876 |
| 2024 Q1 | Price T Rowe Associates Inc md/ |
+20.17%
|
3,489,709 | $54,999 |
| 2024 Q1 | Paradigm Biocapital Advisors L.P. |
+136.23%
|
944,917 | $14,891,892 |
| 2024 Q1 | Boxer Capital |
Opened
|
450,000 | $7,092,000 |
| 2024 Q1 | Morgan Stanley |
+70.21%
|
1,037,409 | $16,349,566 |
| 2024 Q1 | Woodline Partners L.P. |
+31.24%
|
1,437,026 | $22,647,530 |
| 2024 Q1 | Ubs Ag |
+243,413.64%
|
267,865 | $4,221,552 |
| 2024 Q1 | Two Sigma Investments, L.P. |
Opened
|
244,995 | $3,861,121 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Eventide Asset Management | 20.28% | 11,574,821 | |
| Fmr | 18.65% | 10,644,024 | |
| Matrix Capital Management , L.P. | 16.12% | 9,199,973 | |
| Vanguard Group Inc | 9.18% | 5,236,663 | |
| Blackrock | 8.14% | 4,645,758 | |
| State Street Corp | 6.63% | 3,785,652 | |
| Price T Rowe Associates Inc md/ | 6.11% | 3,489,709 | |
| T. Rowe Price Investment Management | 5.82% | 3,319,086 | |
| Capital International Investors | 5.48% | 3,127,758 | |
| Decheng Capital Management Iii (cayman) | 3.68% | 2,099,583 |
Sign up